Moreover, the treatments currently available for HFpEF including sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 (GLP-1) agonists were not originally developed as part of the treatment for clinical syndrome, but rather for type 2 diabetes mellitus (T2DM) and obesity [7]. This evidence concerns the gene GCG and diabetes mellitus.